Bionet - Asset Resilience Ratio

Latest as of June 2026: 41.08%

Bionet (1784) has an Asset Resilience Ratio of 41.08% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Bionet to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

NT$1.27 Billion

≈ $39.87 Million USD Cash + Short-term Investments

Total Assets

NT$3.08 Billion

≈ $97.05 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Bionet's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Bionet total assets.

Liquid Assets Composition Over Time

This chart breaks down Bionet's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of Bionet for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$1.27 Billion	41.08%
Total Liquid Assets	NT$1.27 Billion	41.08%

Asset Resilience Insights

Very High Liquidity: Bionet maintains exceptional liquid asset reserves at 41.08% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Bionet Industry Peers by Asset Resilience Ratio

Compare Bionet's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Fleury S.A. SA:FLRY3	Diagnostics & Research	13.87%
Australian Clinical Labs Ltd AU:ACL	Diagnostics & Research	4.11%
Healius Ltd AU:HLS	Diagnostics & Research	0.06%
Scope Fluidics SA WAR:SCP	Diagnostics & Research	16.51%
RHYTHM Biosciences Ltd AU:RHY	Diagnostics & Research	2.74%
Sonic Healthcare Ltd AU:SHL	Diagnostics & Research	0.13%
Integral Diagnostics Ltd AU:IDX	Diagnostics & Research	0.03%
Monash Ivf Group Ltd AU:MVF	Diagnostics & Research	1.60%

Annual Asset Resilience Ratio for Bionet (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Bionet.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	37.17%	NT$1.14 Billion ≈ $36.07 Million	NT$3.08 Billion ≈ $97.03 Million	-5.10pp
2024-12-31	42.27%	NT$1.33 Billion ≈ $42.03 Million	NT$3.16 Billion ≈ $99.44 Million	+13.79pp
2023-12-31	28.48%	NT$668.86 Million ≈ $21.07 Million	NT$2.35 Billion ≈ $74.00 Million	+13.40pp
2022-12-31	15.08%	NT$277.20 Million ≈ $8.73 Million	NT$1.84 Billion ≈ $57.93 Million	+0.32pp
2021-12-31	14.76%	NT$263.29 Million ≈ $8.30 Million	NT$1.78 Billion ≈ $56.20 Million	-0.32pp
2020-12-31	15.08%	NT$261.59 Million ≈ $8.24 Million	NT$1.73 Billion ≈ $54.65 Million	-3.08pp
2019-12-31	18.16%	NT$319.78 Million ≈ $10.07 Million	NT$1.76 Billion ≈ $55.49 Million	+0.20pp
2018-12-31	17.96%	NT$320.20 Million ≈ $10.09 Million	NT$1.78 Billion ≈ $56.18 Million	-2.12pp
2017-12-31	20.08%	NT$366.44 Million ≈ $11.54 Million	NT$1.82 Billion ≈ $57.50 Million	--

pp = percentage points

About Bionet

TWO:1784 Taiwan Diagnostics & Research

Market Cap

$100.34 Million

NT$3.18 Billion TWD

Market Cap Rank

#19254 Global

#1082 in Taiwan

Share Price

NT$61.30

Change (1 day)

-1.92%

52-Week Range

NT$56.10 - NT$115.50

All Time High

NT$161.50